Comparison of Enoxaparin, Hirulog, and Heparin as Adjunctive Antithrombotic Therapy during Thrombolysis with rtPA in the Stenosed Canine Coronary Artery

Summary

A canine model of electrolytic injury-induced coronary artery thrombosis and rtPA-induced thrombolysis was used to evaluate the relative antithrombotic efficacy of enoxaparin (a low molecular weight heparin), conventional therapy (heparin or heparin plus aspirin), and hirulog (a direct thrombin inhibitor), when used as adjunctive therapy during thrombolysis. After 60 min of clot aging, adjunctive therapy was begun at doses which elevated APTT approximately 2-fold over baseline. Fifteen minutes after the start of adjunctive therapy, recombinant tissue plasminogen activator (rtPA) was administered (100 μg/kg i.v. bolus + 20 μg/kg/min for 60 min). Adjunctive therapy continued for 1 h after termination of rtPA and blood flow was monitored for two additional hours. Enoxaparin (1 mg/kg i.v. bolus + 30 μg/kg/min, n = 10 for each treatment group) was the only adjunctive treatment that significantly increased the total minutes of flow (143 ± 25 min out of a possible 240 min, vs 54 ± 25 min for vehicle, p <0.05) and decreased thrombus mass (6.0 ± 1.3 mg vs 11.8 ± 3.2 mg for vehicle). Although hirulog (2 mg/kg i.v. bolus + 40 μg/kg/min) did not significantly increase the minutes of flow (120 ± 27 min, p <0.06) or decrease thrombus mass (8.7 ± 1.7 mg) compared to vehicle, these values were not significantly different than those measured in the enoxaparin group. However, the results with hirulog were achieved at the expense of a significantly greater increase in template bleeding time than that measured during enoxaparin treatment. Minutes of flow for heparin (50 U/kg i.v. bolus + 0.6 U/kg/min) and heparin plus aspirin (5 mg/kg i.v. bolus) were 69 ± 20 and 60 ± 23 min, respectively; thrombus masses were 8.2 ±1.3 and 7.3 ±1.0 mg, respectively. In summary, enoxaparin was more effective than conventional therapy in this model in terms of vessel patency and thrombus mass, and was as effective as hirulog, at least at a dose of hirulog that only modestly impaired hemostasis. Therefore, enoxaparin may prove to be a safe and effective alternative agent for adjunctive therapy during thrombolysis with rtPA.

• References

• 1 Verheugt FWA, Meijer A, Lagrand WK, VanEenige MJ. Reocclusion: The flip side of coronary thrombolysis. J Am Coll Cardiol 1996; 27: 766-773
• 2 Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Elise S, Sigmon KN, Kereakes D, George B. Stack R and the TAMI study group. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990; 82: 781-791
• 3 Meyer BJ, Badimon JJ, Mailhac A, Femandez-Ortiz A, Chesebro JH, Fuster V, Badimon L. Inhibition of growth of thrombus on fresh mural thrombus. Circulation 1994; 90: 2432-2438
• 4 Eitzman DT, Chi L, Saggin L, Schwartz RS, Lucchesi BR, Fay WP. Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. Circulation 1994; 89: 1523-1529
• 5 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clotbound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin-III-independent inhibitors. J Clin Invest 1990; 86: 385-391
• 6 Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83: 1048-1056
• 7 Rigel DF, Olson RW, Lappe RW. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis. Circulation Res 1993; 72: 1091-1102
• 8 Jackson CV, Wilson HC, Growe VG, Shuman RT, Gesellchen PD. Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: A comparison with heparin in a canine model of coronary artery thrombosis. J Card Pharmacol 1993; 21: 587-594
• 9 Mellot MJ, Connolly TM, York SJ, Bush LR. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis. Thromb Haemost 1990; 64: 526-534
• 10 Rubsamen K, Homberger W. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: Comparison of PEG-hirudin and unfractionated heparin. Thromb Haemost 1996; 76: 105-110
• 11 Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E. for the TIMI 5 Investigators. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994; 23: 0993-1003
• 12 Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995; 91: 2132-2139
• 13 Antman EM. for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996; 94: 911-921
• 14 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-782
• 15 Gold HK, Torres FW, Garabedian HD, Werner W, Jang I-K, Khan A, Hagstrom JN, Yasuda T, Leinbach RC, Newell JB, Bovill EG, Stump DC, Collen D. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Col Cardiol 1993; 21: 1039-1047
• 16 Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparin and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis. Brit Med J 1994; 309: 299-304
• 17 Samama CM, Combe S, Ill P, Barr E, Dreux S, Viars P. Are low-molecular- weight heparins useful for the prophylaxis and treatment of arterial thrombi? Haemostasis 1996; 26 (suppl 2):. 57-64
• 18 Nicolini FA, Nichols WW, Saldeen TG, Khan S, Mehta JL. Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis. Am Heart J 1992; 124: 280-288
• 19 Glick A, Komowski Y, Koifman B, Roth A, Laniado S, Keren G. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996; 77: 1145-1148
• 20 Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-568
• 21 Fujita M, Sasayama S, Kato K, Takaori S. and the Enoxaparin Study Group Kyoto, Japan. Prospective, randomized, placebo-controlled, double-blind, multicenter study of exercise with enoxaparin pretreatment for stable-effort angina. Am Heart J 1995; 129: 535-541
• 22 Melandri G, Semprini F, Cervi V, Candiotti N, Palazzini E, Branzi A, Magnani B. Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. Circulation 1993; 88: 2517-2523
• 23 Frydman A, Bara L, LeRoux Y, Woler M, Chauliac F, Samama M. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in man, given in single subcutaneous doses of 20 up to 80 mg. J Clin Pharm 1988; 28: 609-618
• 24 Dawes J, Bara L, Billaud E, Samama M. Relationship between biological activity and concentration of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis 1986; 16: 116-122
• 25 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 01-17
• 26 Strassen J-M, Rapold HJ, Vanlinthout I, Collen D. Comparative effects of enoxaparin and heparin on arterial and venous clot lysis with alteplase in dogs. Thromb Haemost 1993; 69: 454-459
• 27 Mestre M, Uzan A, Sedivy P, Cavero I. Enoxaparin (Clexane®, Lovenox®), a low molecular weight heparin, enhances t-PA-induced coronary thrombus lysis in anesthetized dogs without inducing hypocoagulability. Thromb Res 1992; 66: 191-206
• 28 Mestre M, Clairefond P, Mardiguian J, Trillou M, Le Fur G, Uzan A. Comparative effects of heparin and PK10169, a low molecular weight fraction, in a canine model of arterial thrombosis. Thromb Res 1985; 38: 389-399
• 29 Brace LD, Fareed J. Heparin-induced platelet aggregation: Dose/response relationships for a low molecular weight heparin derivative (PK-10169) and its subfractions. Thromb Res 1986; 42: 769-782
• 30 Mirshahi M, Soria J, Neuhart E, Steg PG, Jacob P, Combe S, Soria C. Effect of heparin and enoxaparin on platelet interaction with fibrin clots. Thromb Res 1992; 65: 187-191
• 31 Bush LR, Shebuski RJ. In vivo models of arterial thrombosis and thrombolysis. FASEB J 1990; 4: 3087-3098
• 32 Gerotziafas GT, Bara L, Bloch MF, Makris PE, Samama MM. Treatment with LMWHs inhibits Factor Vila generation during in vitro coagulation of whole blood. Thromb Res 1996; 81: 491-496
• 33 Sitko GR, Ramjit DR, Stabilito n, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992; 85: 805-815
• 34 Antman EM. for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-1630
• 35 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Ila Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-1637
• 36 The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Col Cardiol 1997; 1474-1482
• 37 Rote WE, Mu D-X, Bates ER, Nedelman MA, Lucchesi BR. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model.II. Adjunctive therapy with rhirudin. J Card Pharmacol 1994; 23: 203-211
• 38 Mickelson JK, Hoff PT, Homeister JW, Fantone JC, Lucchesi BR. High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury. J Am Col Cardiol 1993; 21: 502-510
• 39 Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang I-K, Holt R, Fallon JT, Collen D. Comparative effects of aspirin, a synthetic thrombin inhibitor, and a monoclonal antiplatelet glycoprotein Hb/Ha antibody on coronary artery reperfusion, reocclusion, and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16: 714-722
• 40 Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 1994; 89: 1802-1809
• 41 Prager NA, Torr-Brown SR, Sobel BE, Abendschein DR. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. J Am Col Cardiol 1993; 22: 296-301